United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during ...

Commonwealth Equity Services LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 3.7% during ...

Investors in United Therapeutics Corp (Symbol: UTHR) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other best healthcare stocks for long-term investment. In the US, healthcare ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands ...

CHRISTOPHER PATUSKY, a director at $UTHR, sold 736 shares of the company on 03-19-2025 for an estimated $229,791. We received data on the trade from a recent SEC ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), United Therapeutics (UTHR – Research Report) and Universal ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...